Evidence map›Paper›PMID 34426762›Full record

ReviewComputational and structural biotechnology journal2021

Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery.

Zhonglei Wang, Liyan Yang, Xian-En Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Structural aspects of enzymes involved in prokaryotic Gram-positive heme biosynthesis.Computational and structural biotechnology journal · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Fullerenes against COVID-19: Repurposing CMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhonglei WangKey Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, PR China.
Liyan YangSchool of Physics and Physical Engineering, Qufu Normal University, Qufu 273165, PR China.
Xian-En ZhaoKey Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safer and more-effective drugs are urgently needed to counter infections with the highly pathogenic SARS-CoV-2, cause of the COVID-19 pandemic. Identification of efficient inhibitors to treat and prevent SARS-CoV-2 infection is a predominant focus. Encouragingly, using X-ray crystal structures of therapeutically relevant drug targets (PL

Indexed as

3CLpro, 3C-Like proteaseACE2, angiotensin-converting enzyme 2Candidate drugsCo-crystal structuresCOVID-19, coronavirus disease 2019cryo-EM, cryo-electron microscopyDyKAT, dynamic kinetic asymmetric transformationEBOV, Ebola virusEC50, half maximal effective concentrationEMD, Electron Microscopy DataFDA-approved drugsFDA, U.S. Food and Drug AdministrationHCoV-229E, human coronavirus 229EHPLC, high-performance liquid chromatographyIC50, half maximal inhibitory concentrationMD, molecular dynamicsMERS-CoV, Middle East respiratory syndrome coronavirusMMPBSA, molecular mechanics Poisson-Boltzmann surface areaMpro, main proteaseMTase, methyltransferaseNatural productsNsp, nonstructural proteinPDB, Protein Data BankPLpro, papain-like proteaseRdRp, RNA-dependent RNA polymeraseRTP, ribonucleoside triphosphateSAM, S-adenosylmethionineSARS-CoV-2SARS-CoV-2, severe acute respiratory syndrome coronavirus 2SARS-CoV, severe acute respiratory syndrome coronavirusSI, selectivity indexUgi-4CR, Ugi four-component reaction

Identifiers

PMID34426762
PMCPMC8373586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.